Stem cell treatments, research and technology is permanent fixture in 21st century medical research. Continued efforts to research and develop embryonic stem cell treatments and procedures doesn't merely mean cloning human beings or involve moral and ethical controversies or issues surrounding such research. Embryonic stem cells provide the basic building blocks and structure of the development of various cellular and tissue structure in the human body, and stem cell research irrefutably offers potential treatments that may eventually cure many disease processes, enable people with spinal cord injuries to walk again, and guide researchers to develop medications that will end to cognitive impairment diseases such as Alzheimer's and Parkinson's Disease.

Millions of cells found in the human body can and are being developed for future medical treatments. Stem cells contain specific instructions on how cellular structures replicate and function. Each cell is also programmed with how long it will live, it's specific functions and tasks.

Stem cells come from different sources. The most commonly studied, and used, stem cell therapies involve:

* Embryonic stem cell therapy
* Adult stem cell therapy and research
* Umbilical cord stem cell therapy

EmCell Therapy
Professor Alexander Smikodub, M.D., PhD, is the founder of the Cell Therapy Clinic of the National Medical University and EmCell Clinic, as well as the inventor of treatment methods using embryonic stem cells in . The EmCell therapy clinic has been offering embryonic stem cell treatments in vivo to improve physical health for nearly two decades and has helped thousands of people suffering from disease processes like Parkinson's, multiple sclerosis, diabetes, various types of muscular dystrophy, blood diseases and cancers.

Dr. Smikodub has performed thousands of embryonic stem cell transplants to international patients who arrived every month from foreign destinations such as China, Germany, and the United States (where stem cell therapy treatments have not been approved) to receive treatments that improve quality of life.

International Clinical Experience
The EmCell Therapy Clinic is one of the world's largest fetal or embryonic stem cell transplantation centers that addresses various conditions and disease processes. Embryonic stem cell research and development continues to offer curative effects, which is one of the most promising aspects of cell research and therapies. The am so clinic focuses their attention on embryonic stem cell transplantation related transplantation of the basic building blocks of all tissues and organs, not the tissues or organs themselves, that are responsible for various functions in the body and provide the basic structures for musculature, blood, immune system, nervous and other body systems.

Stem cell therapies, and most potentially the potential of utilizing embryonic stem cells offer a multitude of benefits including but not limited to enabling cells to migrate directly to the site of injury or damage for repair or replication, establishing intercellular linkage and differentiation (developing into specific cellular structures such as muscle tissue, heart tissue, or neural tissues), In addition, benefits include enhancing immune responses and reducing and avoiding tissue and organ rejection.

EmCell, based in Kiev, Ukraine, was founded in 1994, a private clinic that has gained international recognition and reputation in the field of embryonic stem cell research and clinical applications. Focusing on effective prevention and antiaging programs, and devising and developing treatments and follow-up for complex clinical cases, the EmCell clinic focuses on indications as well as contraindications for severe acquired and genetic disease processes that are caused by decreased cell counts.

Embryonic stem cell research and development continues to be the most effective stem cell therapy yet developed by researchers and scientists. Embryonic stem cells are commonly cultivated from discarded fetuses or embryos resulting from abortions, and can be utilized to provide life-saving treatments for dozens of disease processes and health conditions.

Medical Stem Cell Tourism
The United States does not currently approve of stem cells therapy options, but Americans and other international travelers seek international destinations for promising treatments. Today, thousands of medical tourists venture to locations throughout the world, including China, Thailand, Japan, Europe, and India for treatments that offer beneficial and promising results.

The cost of therapies is determined according to geographic location of treatment facilities as well as the injury, illness or disease being treated. The U.S. is currently funding Phase I clinical trials of some types of stem cell therapies that may provide productive and beneficial use in the near future. In the meantime, individuals can reap the benefits of stem cell research and therapies offered around the world, such as the facilities found at EmCell Therapy in Kiev, Ukraine.
For contact please call or email us at:

Phone: +1.303.317.3607
Email: info@placidway.com

or visit our website:
http://www.placidway.com/package/162


Having trouble viewing this email Click here http://campaign.constantcontact.com/renderv0018iMS5L3VR6PMvYoYIgqFflzayI3Y0hDBkgAP8Fbazel7c38ZYXYIQmLplBBqyBmcjnD9h9NVcYTHk2JDDQezx2w47c8YFHpfh6zect5iRNzeJsZAxGcQIg%3D%3D 3-24-10 Small Cap Daily by SmallCapVoice.com -------------------------------------- Yesterday`s Top Performers -------------------------------------- Company: VitaminSpice (OTCBB: VTMS) End of day:

Price: 0.46 Change (%): + 0.01 (2.22) Volume: 23,900 http://bit.ly/9SBxNf ----------------------------- Hot Stocks To Watch ----------------------------- Company: Extensions, Inc. (Pink Sheets: EXTI) End of day:

Price: 0.16 Change (%): - 0.02 (11.11) Volume: 14,830 http://bit.ly/alu5n6 Jack Canfield Endorses Newswire Publishing`s "Confessions of a Bank Director" as a Must Read HOUSTON, March 24, 2010 (GLOBE NEWSWIRE) Newswire.Net, a subsidiary of Extensions, Inc. (Pink Sheets:EXTI), announced today that Jack Canfield, the Co-Author of the Chicken Soup for the Soul series has endorsed Dr. Barkat Charanias book titled Confessions of a Bank Director: The Entrepreneurs Guide to Credit, Capital and Cash Flow as a must read.

Read More http://bit.ly/dvHfRZ ----------------------------------------- SmallCapVoice Clients` News ----------------------------------------- Company: Freshwater Technologies, Inc. (OTCBB: FWTC) Freshwater Increases Technical Support for FW Water Activation Products Mar. 23, 2010 (Business Wire) Freshwater Technologies Inc. (OTCBB: FWTC) is pleased to announce that it will be adding up to 5 new FW Activator technical consultants over the next year to service the Latin American Countries where it distributes the FW Activator. Freshwaters water activation technology has attracted significant commercial interest in the ability to solve a number of water treatment applications, including heating and cooling, greenhouse agriculture and manufacturing productivity. The addition of these experienced FW Activator technical consultants will greatly support our local distributors and agents in sales presentations, Activator installation and customer service.

Read More http://bit.ly/cEi1fy -------------------------------- Other Small Cap News -------------------------------- Company: Bell Microproducts Inc. (Nasdaq: BELM) http://bit.ly/dkAPMZ Bell Microproducts` Latin America Division Signs Agreement With Dell Addition of Dell`s Consumer Product Line Strengthens Bell Micro Latin America`s Offerings in Growing Mobility Space SAN JOSE, Calif., March 23, 2010 (GLOBE NEWSWIRE) -- Bell Microproducts Inc.. (Nasdaq:BELM), one of the world`s largest value-added distributors of storage and computing technology, today announced that its Latin American division has signed a distribution agreement with Dell Inc. Under the terms of the agreement, Bell Micro will distribute Dell laptops and netbooks to retailers and SMBs throughout Latin America.

Read More http://bit.ly/a7eeEw ------------------------------------------------------------- Company: Z-AXIS, Inc. (Nasdaq: VIDE) http://bit.ly/bK9VnD Z-AXIS Begins New Fiscal Year With Record Backlog; Adds US Manufacturing Capacity PHELPS, N.Y., March 23, 2010 (GLOBE NEWSWIRE) -- Z-AXIS, Inc., a wholly-owned subsidiary of Video Display Corporation (Nasdaq:VIDE), begins its February 28, 2011 fiscal year with a record backlog, more than 50% greater than the previous fiscal year. The US-based electronics design and manufacturing company achieved steady quarter-to-quarter growth during its fiscal year ended Feb. 28, 2010, and is planning for accelerated growth based on current bookings for products to be delivered this year.

Read More http://bit.ly/bLBiGx ------------------------------------------------------------ Company: NexMed, Inc. (Nasdaq: NEXM) http://bit.ly/awwYI4 NexMed, Inc. Enters into Distribution Agreement for Japan SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a company with a revenue generating discovery pre-clinical CRO and a pipeline of products based on the NexACT(R) technology, today announced that its wholly-owned subsidiary, Bio-Quant has signed a distribution agreement with Cosmo Bio Co., Ltd, under which Cosmo Bio will market Bio-Quants discovery and pre-clinical contract research services throughout Japan.

Read More http://bit.ly/bbb2ZP -------------------------------------------------------------------------- Company: Competitive Technologies, Inc. (NYSE Amex: CTT) http://bit.ly/a0B3TT Competitive Technologies` Calmare(R) Therapy Medical Device Treating Cancer Patients in Virginia FAIRFIELD, Conn., March 23, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced that a premier physician oncology practice based in Virginia has begun using CTT`s Calmare(R) Therapy pain therapy medical device to treat patients suffering from pain related to cancer, under the direction of several medical oncologists. This group with more than 30 years of experience caring for cancer patients is affiliated with a national cancer treatment and research network.

Read More http://bit.ly/cWatms -------------------------------------------------------------------------------- Company: Flexible Solutions International, Inc. (NYSE Amex: FSI) http://bit.ly/9T3MQT FSI Announces Fourth Quarter, 2009 Revenue Exceeds 2008 Period Despite the recent economic slow down, orders continue to increase in all product lines as distributors face depleted inventories and the economy continues to improve. The result is an increase in fourth quarter (Q4), 2009 revenue to $2.40million, up from $2.24million in Q4, 2008, or a year over year increase of 7%. Combined with the significant increase in Q3 09 [sales up 17%] and compared with the revenue declines seen during first and second quarters of 2009, this consecutive increase in sales confirms the possibility of a significant reversal in the revenue trend for the Company.

Read More http://bit.ly/c6BbPw ------------------------------------------------------------------ Company: MF Global Holdings Ltd. (NYSE: MF) http://bit.ly/93a99j MF Global Appoints Jon S. Corzine Chairman and Chief Executive Officer Former Chairman and Senior Partner of Goldman Sachs, New Jersey Governor and U.S. Senator to Join International Brokerage Firm Company Provides Update on Fourth Quarter Financial Performance NEW YORK--(BUSINESS WIRE)--MF Global Holdings Ltd. (NYSE: MF), a leading broker offering customized solutions in global cash and derivatives markets, today announced that its board of directors has appointed Jon S. Corzine as chairman and chief executive officer, effective immediately.

Read More http://bit.ly/aSt8Kp ------------------------------------------------------------ Company: Sprint (NYSE: S) http://bit.ly/bLY85Z World`s First 3G/4G Android Phone, HTC EVOTM 4G, Coming this Summer Exclusively from Sprint HTC EVO 4G offers one of the most robust multimedia experiences on a wireless phone today; features Android(TM) 2.1, one of the industry`s largest touch-screen displays, 8.0 MP camera, HD video capture, HDMI output, Mobile Hotspot capability and HTC Sense(TM) Sprint (NYSE: S) and HTC Corporation today announced summer availability of the worlds first 3G/4G Android handset, HTC EVO 4G exclusively from Sprint. HTC EVO 4G delivers a multimedia experience at 4G speeds that is second to none, making it possible to download music, pictures, files, or videos in seconds not minutes and watch streaming video on the go with one of the largest pinch-to-zoom displays, at 4.3 inches, in the wireless industry.

Read More http://bit.ly/aWy8of ----------------------------------------------------------------- Company: Gentium S.p.A. (Nasdaq: GENT) http://bit.ly/aNAjmH Gentium Announces Defibrotide Results Highlighted at Opening Session and Symposium at EBMT Annual Meeting Gentium S.p.A. (Nasdaq:GENT) today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation (EBMT) 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician`s program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.

Read More http://bit.ly/aYDE3O ------------------------------------------------------------------------- Company: Arena Pharmaceuticals Inc. (Nasdaq: ARNA) http://bit.ly/aqYy8A Arena Pharmaceuticals starts narcolepsy drug study Arena Pharmaceuticals starts early-stage study on potential narcolepsy drug SAN DIEGO (AP) -- Development-stage biotechnology company Arena Pharmaceuticals Inc. said it started an early-stage study of a potential narcolepsy and cataplexy treatment.

Narcolepsy is a sleep disorder and cataplexy is a sudden loss of muscle tone that frequently affects people with narcolepsy.

Read More http://bit.ly/bSd7UR ----------------------------------------------------------------------------- Company: Aastrom Biosciences, Inc. (Nasdaq: ASTM) http://bit.ly/cX29et Aastrom Announces Treatment of Final Patient in RESTORE-CLI Clinical Trial Company Plans to Initiate Phase 3 Planning Discussions With the FDA and Report Six-Month Interim Results for all Enrolled Patients Later This Year Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the final patient has been treated in the company`s ongoing multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. This patient received intramuscular injections of either Aastrom`s tissue repair cells (TRCs) or electrolyte solution (placebo) for the treatment of critical limb ischemia (CLI), the end-stage of peripheral arterial disease. People with CLI face a high risk of amputation and, in some cases, death. Approximately 1 million people in the U.S. suffer from CLI, which results in more than 160,000 amputations each year.

Read More http://bit.ly/d0RwZT ------------------------------------------------------------------- Company: FuelCell Energ (Nasdaq: FCEL) http://bit.ly/d2Vsv5 FuelCell Energy Announces Passage of Renewable Portfolio Standard by South Korean National Assembly FuelCell Energy`s Direct FuelCell(R) Power Plants Operating on Both Biogas and Natural Gas Qualify Under the New Program FuelCell Energy (Nasdaq:FCEL), a leading manufacturer of high efficiency ultra-clean power plants using renewable and other fuels for commercial, industrial, government and utility customers, today announced the passage of a Renewable Portfolio Standard (RPS) by the National Assembly of the Republic of Korea, requiring 4 percent clean energy generation by 2015 and 10 percent by 2022.

Read More http://bit.ly/a703Fg --------------------------------------------------------------------- Company: OceanFreight Inc. (Nasdaq: ONCF) http://bit.ly/bBzoK6 OceanFreight Inc. Announces an Order for Three VLOCs OceanFreight Inc. (NASDAQ:OCNF), a global provider of seaborne transportation services for both drybulk and energy commodities, announced today that it has entered into an agreement to build three 206,000 DWT Very Large Ore Carriers (VLOCs) at Shanghai Waigaichao Shipbuilding. Two of the vessels are scheduled to be delivered in the second and fourth quarters of 2012 and the third vessel is scheduled to be delivered in the first quarter of 2013. The total purchase price for the three vessels is approximately $204 million..

Read More http://bit.ly/9EG5wD ------------------ MarketNews ------------------ By Jennifer Loven: AP White House Correspondent It`s the law of the land: Health overhaul signed Jubilant Obama signs historic health overhaul after long struggle -- political fight continues WASHINGTON (AP) -- Claiming a historic triumph that could define his presidency, a jubilant Barack Obama signed a massive, nearly $1 trillion health care overhaul on Tuesday that will for the first time cement insurance coverage as the right of every U.S. citizen and begin to reshape the way virtually all Americans receive and pay for treatment.

After more than a year of hyperpartisan struggle -- and numerous near-death moments for the measure -- Obama declared "a new season in America" as he sealed a victory denied to a line of presidents stretching back more than half a century. Democratic lawmakers cheered him on, giving the White House signing ceremony a rally-like atmosphere as they shouted and snapped photos with pocket cameras or cell phones.

Read More http://bit.ly/9fUwyP ------------------------------------------------------------------------ By Martin Crutsinger: AP Economics Writer February durable goods orders up 0.5 percent Durable goods orders rise for third month, led by higher demand for aircraft and machinery WASHINGTON (AP) -- Orders for big-ticket manufactured goods rose for a third consecutive month in February, bolstered by strong demand for commercial aircraft and machinery. The hope is that continued strength in manufacturing will help sustain the economic recovery.

The Commerce Department said Wednesday that orders for durable goods advanced 0.5 percent last month, slightly lower than the 0.7 percent gain that economists had expected.

Read More http://bit.ly/bgm4XP --------------- Disclaimer --------------- You are receiving this e-mail because you either opted into to our mailing list at smallcapvoice.com or at one of our Money Show exhibits. You may opt out at any time by clicking on the Safe